{"id":"NCT01343082","sponsor":"Santen Pharmaceutical Co., Ltd.","briefTitle":"DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","officialTitle":"A Long-term Open-label Study of DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension -Phase 3-","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-05","primaryCompletion":"2013-03","completion":null,"firstPosted":"2011-04-27","resultsPosted":"2015-05-14","lastUpdate":"2015-06-15"},"enrollment":148,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma or Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"DE-111 ophthalmic solution","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"Safety and IOP (intraocular pressure) lowering effect of DE-111 ophthalmic solution will be evaluated in open-angle glaucoma or ocular hypertension patients, in an open-label, multicenter study.","primaryOutcome":{"measure":"Change From Baseline in IOP (Intraocular Pressure) at End of Study","timeFrame":"Treatment period: Week 0 (Baseline) and Week 52 (End of Study)","effectByArm":[{"arm":"DE-111","deltaMin":-1.8,"sd":2.2}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":136},"commonTop":["Growth of eyelashes","Nasopharyngitis","Punctate keratitis","Conjunctival hyperaemia","Blepharal pigmentation"]}}